Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients

NCT03113604 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT03113604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Overall status
Withdrawn
Start date
November 20, 2015
Completion date
November 20, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, hepatocyte receptor